Trial Profile
The Clinical Study of Rituximab Combined With Mesenchymal Stem Cells in the Treatment of Primary Nephrotic Syndrome (3-4 Stage of Chronic Kidney Disease)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Oct 2021
Price :
$35
*
At a glance
- Drugs Mesenchymal stem cell therapy (Primary) ; Rituximab (Primary)
- Indications Nephrotic syndrome; Renal failure
- Focus Therapeutic Use
- Acronyms CKD
- 21 Nov 2016 New trial record